This is huge. The FDA just granted orphan drug designation (ODD) to Insys Therapeutics for its pharmaceutical-grade, proprietary cannabidiol (CBD) product for treating cancer tumors in humans. Although glioma tumors affect less than 200,000 Americans, this FDA approval sets a precedent for natural remedies, and could lead to a revolutionary way to legally treat many forms of cancer with natural cures. In justifying preliminary approval of utilizing CBD to treat brain and spinal cancer tumors of this kind, Insys Therapeutics provided the FDA with the scientific rationale for CBD's benefits, including human experiences with the natural remedy, evidence discovered through in vitro studies, and preclinical animal testing.